IRINOT 100 MG INJ VIAL

About

Irinotecan is an antineoplastic agent classified as a topoisomerase I inhibitor. It exerts its cytotoxic effects by binding to the topoisomerase I-DNA complex, preventing the religation of DNA single-strand breaks, which ultimately leads to DNA damage and apoptosis in rapidly dividing cancer cells. This mechanism is crucial in disrupting the replication and transcription processes essential for tumor growth. Irinotecan is primarily indicated for the treatment of metastatic colorectal cancer, often used in combination with other chemotherapeutic agents.

The drug is administered intravenously and is a prodrug, converted in the liver by carboxylesterases to its active metabolite, SN-38, which is significantly more potent. Its efficacy in advanced malignancies underscores its role in modern oncology, particularly in patients who have progressed on or are intolerant to fluorouracil-based therapies. Careful monitoring for adverse effects, especially myelosuppression and diarrhea, is essential during treatment.

Uses

• Metastatic colorectal cancer
• Advanced pancreatic cancer (off-label)
• Small cell lung cancer (off-label)
• Other solid tumors (investigational)

Directions For Use

Administered intravenously by a qualified healthcare professional. Dosage and infusion rate are determined by the physician.

Benefits

• Effective against certain types of cancer
• Can prolong survival in metastatic disease
• Part of established chemotherapy regimens
• Offers treatment option for refractory cancers
• May improve disease control
• Administered by healthcare professionals

Side Effects

• Severe diarrhea (early and late)
• Myelosuppression (neutropenia)
• Nausea and vomiting
• Abdominal pain
• Alopecia (hair loss)
• Fatigue and asthenia
• Fever
• Mucositis
• Cholinergic syndrome
• Elevated liver enzymes
• Anemia
• Thrombocytopenia

Safety Measures

• Alcohol - Avoid alcohol consumption during Irinotecan treatment due to potential for increased gastrointestinal side effects and liver strain.
• Pregnancy - Irinotecan is contraindicated in pregnancy due to its teratogenic potential; effective contraception is required during and after treatment.
• Breastfeeding - Breastfeeding is contraindicated during Irinotecan therapy and for a period after, as the drug may be excreted in breast milk.
• Liver - Use with caution in patients with hepatic impairment; dose adjustments may be necessary, and liver function should be closely monitored.
• Kidney - Use with caution in patients with renal impairment; dose adjustments may be considered, and kidney function should be monitored.
• Lung - Monitor for signs of interstitial lung disease or pulmonary toxicity, though rare, as it can be a serious adverse effect.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.